Expert Interview
A third look: Discussing the current standard of care for celiac and new therapies in development such as TAK 101; an immune modifying nanoparticle designed to induce gluten-specific tolerance currently in development by Takeda Pharm
Ticker(s): TAK- Gastroenterology specialist affiliated with Saint Mary's Hospital.
- Has been in practice 44 years with extensive experience in Esophageal Disorders
- Specializes in advanced endoscopic interventional and is experienced in inflammatory bowel disease, interventional gastroenterology, celiac disease, parenteral nutrition, and autoimmune gastroenterology.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
